RE:Conditions are right for biopharma M&A to break out“It’s an interesting time, right on this perfect storm for biotechs and where big pharmas are in terms of building out their core specialty areas and having capital to deploy,” O’Brien said. “I think it’s a great space.”
Desperate? Only if you are Big Pharma which is facing a looming patent cliff, increased competition from other Big Biophamrma companies, and a product pipeline that requires rebuilding of their core specialties, like most Big Pharma's need to accomplish sooner rather than later. Having Big Pharma's face this "perfect storm" is what desperate really looks like.